Epidemiology of neuromyelitis optica in the United States

A multicenter analysis

Maureen A. Mealy, Dean M. Wingerchuk, Benjamin M. Greenberg, Michael Levy

Research output: Contribution to journalArticle

Abstract

Background: Rare diseases require integrated multicenter clinical networks to facilitate clinical research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that are distinct from multiple sclerosis and associated with NMO-IgG, a serologic antibody against aquaporin 4. Objective: To develop a national multicenter NMO clinical consortium and report initial demographic, clinical, and radiographic features of a cohort of patients with NMO/NMOSD in the United States. Design: Review of medical records from patients undergoing evaluation during a 5-year period. We used uniform diagnostic criteria and clinical, laboratory, and neuroimaging definitions to describe the cohort. Setting: Three academic medical centers. Patients: One hundred eighty-seven patients with NMO/NMOSD. Results: Of the 187 patients included in the analysis, 86 had NMO-IgG-seropositive NMO; 40, NMO-IgG-seronegative NMO; and 61, NMO-IgG-seropositive NMOSD. Altogether, 29.4% of our patients were initially misdiagnosed with multiple sclerosis. The average age at onset of NMO/NMOSD was 41.1 years with a strong female predilection, similar to other autoimmune disorders. Nonwhite patients constituted 52.4% of the cohort. The hallmark of NMO and NMOSD is recurrent longitudinally extensive transverse myelitis, but patients with NMO tend to initially present with optic neuritis. Conclusions: A national multicenter consortium to study NMO/NMOSD is feasible and facilitates accurate clinical diagnosis. This network establishes a foundation for determining disease prevalence, translational research, and clinical trials.

Original languageEnglish (US)
Pages (from-to)1176-1180
Number of pages5
JournalArchives of Neurology
Volume69
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Neuromyelitis Optica
Epidemiology
Immunoglobulin G
Multiple Sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Epidemiology of neuromyelitis optica in the United States : A multicenter analysis. / Mealy, Maureen A.; Wingerchuk, Dean M.; Greenberg, Benjamin M.; Levy, Michael.

In: Archives of Neurology, Vol. 69, No. 9, 09.2012, p. 1176-1180.

Research output: Contribution to journalArticle

Mealy, Maureen A. ; Wingerchuk, Dean M. ; Greenberg, Benjamin M. ; Levy, Michael. / Epidemiology of neuromyelitis optica in the United States : A multicenter analysis. In: Archives of Neurology. 2012 ; Vol. 69, No. 9. pp. 1176-1180.
@article{5a05ae2b22f74e42aa6b8c6e676f501a,
title = "Epidemiology of neuromyelitis optica in the United States: A multicenter analysis",
abstract = "Background: Rare diseases require integrated multicenter clinical networks to facilitate clinical research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that are distinct from multiple sclerosis and associated with NMO-IgG, a serologic antibody against aquaporin 4. Objective: To develop a national multicenter NMO clinical consortium and report initial demographic, clinical, and radiographic features of a cohort of patients with NMO/NMOSD in the United States. Design: Review of medical records from patients undergoing evaluation during a 5-year period. We used uniform diagnostic criteria and clinical, laboratory, and neuroimaging definitions to describe the cohort. Setting: Three academic medical centers. Patients: One hundred eighty-seven patients with NMO/NMOSD. Results: Of the 187 patients included in the analysis, 86 had NMO-IgG-seropositive NMO; 40, NMO-IgG-seronegative NMO; and 61, NMO-IgG-seropositive NMOSD. Altogether, 29.4{\%} of our patients were initially misdiagnosed with multiple sclerosis. The average age at onset of NMO/NMOSD was 41.1 years with a strong female predilection, similar to other autoimmune disorders. Nonwhite patients constituted 52.4{\%} of the cohort. The hallmark of NMO and NMOSD is recurrent longitudinally extensive transverse myelitis, but patients with NMO tend to initially present with optic neuritis. Conclusions: A national multicenter consortium to study NMO/NMOSD is feasible and facilitates accurate clinical diagnosis. This network establishes a foundation for determining disease prevalence, translational research, and clinical trials.",
author = "Mealy, {Maureen A.} and Wingerchuk, {Dean M.} and Greenberg, {Benjamin M.} and Michael Levy",
year = "2012",
month = "9",
doi = "10.1001/archneurol.2012.314",
language = "English (US)",
volume = "69",
pages = "1176--1180",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Epidemiology of neuromyelitis optica in the United States

T2 - A multicenter analysis

AU - Mealy, Maureen A.

AU - Wingerchuk, Dean M.

AU - Greenberg, Benjamin M.

AU - Levy, Michael

PY - 2012/9

Y1 - 2012/9

N2 - Background: Rare diseases require integrated multicenter clinical networks to facilitate clinical research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that are distinct from multiple sclerosis and associated with NMO-IgG, a serologic antibody against aquaporin 4. Objective: To develop a national multicenter NMO clinical consortium and report initial demographic, clinical, and radiographic features of a cohort of patients with NMO/NMOSD in the United States. Design: Review of medical records from patients undergoing evaluation during a 5-year period. We used uniform diagnostic criteria and clinical, laboratory, and neuroimaging definitions to describe the cohort. Setting: Three academic medical centers. Patients: One hundred eighty-seven patients with NMO/NMOSD. Results: Of the 187 patients included in the analysis, 86 had NMO-IgG-seropositive NMO; 40, NMO-IgG-seronegative NMO; and 61, NMO-IgG-seropositive NMOSD. Altogether, 29.4% of our patients were initially misdiagnosed with multiple sclerosis. The average age at onset of NMO/NMOSD was 41.1 years with a strong female predilection, similar to other autoimmune disorders. Nonwhite patients constituted 52.4% of the cohort. The hallmark of NMO and NMOSD is recurrent longitudinally extensive transverse myelitis, but patients with NMO tend to initially present with optic neuritis. Conclusions: A national multicenter consortium to study NMO/NMOSD is feasible and facilitates accurate clinical diagnosis. This network establishes a foundation for determining disease prevalence, translational research, and clinical trials.

AB - Background: Rare diseases require integrated multicenter clinical networks to facilitate clinical research. Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) are uncommon neuroinflammatory syndromes that are distinct from multiple sclerosis and associated with NMO-IgG, a serologic antibody against aquaporin 4. Objective: To develop a national multicenter NMO clinical consortium and report initial demographic, clinical, and radiographic features of a cohort of patients with NMO/NMOSD in the United States. Design: Review of medical records from patients undergoing evaluation during a 5-year period. We used uniform diagnostic criteria and clinical, laboratory, and neuroimaging definitions to describe the cohort. Setting: Three academic medical centers. Patients: One hundred eighty-seven patients with NMO/NMOSD. Results: Of the 187 patients included in the analysis, 86 had NMO-IgG-seropositive NMO; 40, NMO-IgG-seronegative NMO; and 61, NMO-IgG-seropositive NMOSD. Altogether, 29.4% of our patients were initially misdiagnosed with multiple sclerosis. The average age at onset of NMO/NMOSD was 41.1 years with a strong female predilection, similar to other autoimmune disorders. Nonwhite patients constituted 52.4% of the cohort. The hallmark of NMO and NMOSD is recurrent longitudinally extensive transverse myelitis, but patients with NMO tend to initially present with optic neuritis. Conclusions: A national multicenter consortium to study NMO/NMOSD is feasible and facilitates accurate clinical diagnosis. This network establishes a foundation for determining disease prevalence, translational research, and clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84866083179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866083179&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2012.314

DO - 10.1001/archneurol.2012.314

M3 - Article

VL - 69

SP - 1176

EP - 1180

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 9

ER -